KMID : 0338420210360051181
|
|
The Korean Journal of Internal Medicine 2021 Volume.36 No. 5 p.1181 ~ p.1189
|
|
Risk factors for neutropenic fever in non- Hodgkin¡¯s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis
|
|
Kim Yu-Ri
Kim Soo-Jeong Park Yong Oh Sung-Yong Yun Hwan-Jung Mun Yeung-Chul
|
|
Abstract
|
|
|
Background/Aims: Febrile neutropenia (FN) interferes with the proper chemotherapy dose density or intensity in non-Hodgkin¡¯s lymphoma (NHL) patients. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ¡¾ rituximab has an intermediate FN risk. Prophylactic granulocyte colony-stimulating factor (G-CSF) support is recommended for patients with other host-related risk factors.
Methods: We evaluated the risk factors for FN-related admission in NHL patients who have received primary G-CSF (lenograstim) prophylaxis.
Results: Data from 148 patients were analyzed. The incidence of neutropenic fever was 96 events (12.2%), and the median period was 3.85 days (range, 0 to 5.9); the median duration of neutropenia was 4.21 days (range, 3.3 to 5.07). Eighty-three FN-related admissions were reported. Advanced age (> 60 years), female sex, a low albumin level, and prednisone use were associated with FN-related admission in multivariable analysis (p = 0.010, p < 0.001, and p = 0.010, respectively). A comparison between diffuse large B-cell lymphoma patients treated with R-CHOP and pegylated G-CSF and those treated with R-CHOP and lenograstim did not reveal significant differences in the FN-related admission rate between the two groups, although the lenograstim-treated group had a higher incidence of severe neutropenia.
Conclusions: Elderly patients, female patients, and patients with low albumin levels need to be actively followed-up for FN even when primary prophylaxis with G-CSF has been used.
|
|
KEYWORD
|
|
Febrile neutropenia, Lymphoma, non-Hodgkin, Elderly, Female, Albumin
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|